Drug Database
AN
Anerdic (Anerdic / DLBS 2411 / DLBS2411)
✓ ApprovedDexa Medica · ATP1A1
What is Anerdic?
Anerdic is a therapeutic agent developed by Dexa Medica. It is approved for therapeutic indications via oral (po).
Drug Profile
| Brand Names | Anerdic, DLBS 2411, DLBS2411 |
| Company | Dexa Medica |
| Molecular Target | ATP1A1 |
| Route | Oral (PO) |
| Status | Approved |
Sources: ClinicalTrials.gov, Dexa Medica
Mechanism of Action
Molecular Targets
Anerdic acts on 1 molecular target:
| ATP1A1 | ATPase Na+/K+ transporting subunit alpha 1 (HOMGSMR2, CMT2DD) |
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.
Therapeutic Indications
Anerdic is developed for 2 unique indications across 1 therapeutic area.
| Therapeutic Area | Condition | Phase |
|---|---|---|
| Gastrointestinal disorders | Gastrooesophageal reflux disease | ✓ Approved |
| Gastrointestinal disorders | Dyspepsia | Phase III |
Related Research Articles
Unable to load articles right now.